ProCE Banner Activity

Phase II PCYC-1121 Trial: Ibrutinib Monotherapy Active in R/R Marginal Zone Lymphoma

Slideset Download
Conference Coverage
Ibrutinib demonstrated an ORR of 48% across patients with 3 different subtypes of relapsed/refractory marginal zone lymphoma.

Released: December 12, 2016

Expiration: December 11, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen